Yoon YH, et al. - Experts assessed the impact of dexamethasone intravitreal implant for macular edema (ME) following branch retinal vein occlusion (BRVO) in Korean patients. They performed a prospective, open-label, multicenter study of patients with ME for < 3 months. Results demonstrated that rapid and significantly better improvement in best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with BRVO-associated ME was provided with intravitreal dexamethasone treatment with an interval of ≥4 months.